Literature DB >> 3022060

[The significance of eicosanoids in glomerular diseases].

R A Stahl.   

Abstract

Prostanoids are local cyclooxygenase products, synthesized by mesangial and epithelial cells of the glomerulus as well as by a variety of inflammatory cells and platelets. Prostaglandins and thromboxane have direct vasodilatory and vasoconstrictory effects and can modulate glomerular function. Arachidonic acid, the main substrate for cyclooxygenase, can also be metabolized by the lipoxygenase pathway to leukotrienes, substances which are primarily synthesized in inflammatory cells. In several models induction of immunologic glomerular injury is associated with an increased glomerular formation of cyclooxygenase and lipoxygenase products. The changes in cyclooxygenase products have been shown to account for some hemodynamic changes found in some of these models. Increased renal prostanoid formation is also present in patients with glomerular disease. There is some evidence that increased renal PG-formation in patients with moderate glomerular disease regulates GFR and mediates proteinurie in some of these patients. Leukotrienes are chemotactive substances which modulate the function of inflammatory cells, stimulate the growth of mesangial cells, and constrict mesangial cells in culture. Thus, these compounds might be mediators in the induction of immune mediated glomerular disease.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3022060     DOI: 10.1007/bf01725553

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  94 in total

Review 1.  Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin.

Authors:  S Moncada; J R Vane
Journal:  Pharmacol Rev       Date:  1978-09       Impact factor: 25.468

2.  Eicosapentaenoic acid and IgA nephropathy.

Authors:  T Hamazaki; S Tateno; H Shishido
Journal:  Lancet       Date:  1984-05-05       Impact factor: 79.321

3.  Membranoproliferative glomerulonephritis. A prospective clinical trial of platelet-inhibitor therapy.

Authors:  J V Donadio; C F Anderson; J C Mitchell; K E Holley; D M Ilstrup; V Fuster; J H Chesebro
Journal:  N Engl J Med       Date:  1984-05-31       Impact factor: 91.245

4.  Pharmacological control of prostaglandin and thromboxane release from macrophages.

Authors:  K Brune; M Glatt; H Kälin; B A Peskar
Journal:  Nature       Date:  1978-07-20       Impact factor: 49.962

5.  Immunohistochemical localization of the prostaglandin-forming cyclooxygenase in renal cortex.

Authors:  W L Smith; T G Bell
Journal:  Am J Physiol       Date:  1978-11

6.  Aspirin-induced depression of renal function.

Authors:  R P Kimberly; P H Plotz
Journal:  N Engl J Med       Date:  1977-02-24       Impact factor: 91.245

7.  Effects of sulindac and ibuprofen in patients with chronic glomerular disease. Evidence for the dependence of renal function on prostacyclin.

Authors:  G Ciabattoni; G A Cinotti; A Pierucci; B M Simonetti; M Manzi; F Pugliese; P Barsotti; G Pecci; F Taggi; C Patrono
Journal:  N Engl J Med       Date:  1984-02-02       Impact factor: 91.245

8.  Prostaglandin and thromboxane synthesis by rat glomerular epithelial cells.

Authors:  A S Petrulis; M Aikawa; M J Dunn
Journal:  Kidney Int       Date:  1981-10       Impact factor: 10.612

9.  Slow reacting substances of anaphylaxis: identification of leukotrienes C-1 and D from human and rat sources.

Authors:  R A Lewis; K F Austen; J M Drazen; D A Clark; A Marfat; E J Corey
Journal:  Proc Natl Acad Sci U S A       Date:  1980-06       Impact factor: 11.205

10.  Prostaglandin synthesis by rat glomerular mesangial cells in culture. Effects of angiotensin II and arginine vasopressin.

Authors:  L A Scharschmidt; M J Dunn
Journal:  J Clin Invest       Date:  1983-06       Impact factor: 14.808

View more
  1 in total

1.  Morphometric investigations on intrarenal vessels of streptozotocin-diabetic rats.

Authors:  H Wehner; G Nelischer
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.